1.
Palliative Care Research
; 17(2):22-00007, 2022.
Article
in Japanese
| J-STAGE | ID: covidwho-1887080
2.
Bioorg Med Chem Lett
; 43: 128052, 2021 07 01.
Article
in English
| MEDLINE | ID: covidwho-1196690
ABSTRACT
Ciclesonide is an inhaled corticosteroid used to treat asthma and is currently undergoing clinical trials for treatment of coronavirus disease 2019 (COVID-19). An active metabolite of ciclesonide, Cic2, was recently reported to repress severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genomic RNA replication. Herein, we designed and synthesized a few types of ciclesonide analogues. Cic4 (bearing an azide group) and Cic6 (bearing a chloro group) potently decreased SARS-CoV-2 viral replication and had low cytotoxicity compared with Cic2 (bearing a hydroxy group). These compounds are promising as novel therapeutic agents for COVID-19 that show significant antiviral activity.